protein biomarkers

Clarient plans to develop a test for diagnosting, selecting therapy, and monitoring drug response in cancer patients.

The firm will use the equity investment from the state to develop its protein biomarker technology.

The chip-based method will capture and release compounds for mass spec analysis.

The firm will use Medical Therapies' midkine patent portfolio to develop lung cancer diagnostics.

The partners will use Horizon's cell lines to identify unique protein biomarker signatures.

BD and Tyrian ended their partnership to develop a point-of-care diagnostic for active tuberculosis because of an inability to consistently detect Tyrian's lead protein biomarker in clinical samples at high enough sensitivity and specificity levels.

The company will analyze protein targets of interest using shotgun mutagenesis mapping technology to identify amino acids essential for antibody binding and to discover and characterize cancer-specific biomarkers.